Aspira Women's Health Q3 product revenue up 26% to $2.0M; CFO departing Dec 1

Aspira Women's Health Inc.

2022-Q3 EPS reported -$0.19 revenue$6,031,000

Q3 product revenue $2.037M (+26% YoY); Ova1Plus volume 5,524 (+29% YoY); gross margin 57%.
CFO Robert Beechey to depart Dec 1; will serve as consultant during successor search.
OvaWatch launch planned Q4 2022; ovarian cancer portfolio rebranded as OvaSuite.
Sponsored research agreement with Harvard Dana Farber, Brigham & Women's, and Medical Univ. of Lodz for endometriosis test.
Co-marketing with BioReference launched in Q4; raised $9M gross ($7.7M net) in public offering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aspira Women's Health Inc. reported the third quarter ended September 30, 2022 results: revenue $2,037,000.

Period: the third quarter ended September 30, 2022
Revenue: $2,037,000
Result: reported results

Exact text from the filing

wish Bob all the best in his future endeavors.” Highlights of Third Quarter 2022 vs. Third Quarter 2021 · Product revenue for the three months ended September 30, 2022 was $2,037,000 compared to $1,617,000 for the same period in 2021, an increase of 26%. The number of Ova1Plus tests performed during the quarter increased 29% to 5,524 compared to 4,281 for the

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-22-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.